FilingSEC EDGAR8-K
Korro Bio Initiates Dosing in Phase 1/2 Clinical Trial of KRRO-121
· SEC accepted
StagePhase 1/2
Filing content
Korro Bio announced that it has dosed the first cohort of participants in its Phase 1/2 clinical trial of KRRO-121 for the treatment of urea cycle disorders and hepatic encephalopathy.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…